Triciribine | VQD-002 | CAS#35943-35-2 | AKT inhibitor

MedKoo Cat#: 203010 | Name: Triciribine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Triciribine, also known as VQD-002, is a potent AKT inhibitor and a cell-permeable tricyclic nucleoside molecule with potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Akts are anti-apoptotic serine/theronine-specific protein kinases that phosphorylate and inactivate components of the apoptotic machinery, including Bcl-xL/Bcl-2-associated death promoter (BAD) and caspase 9.

Chemical Structure

Triciribine

CAS#35943-35-2

Theoretical Analysis

MedKoo Cat#: 203010

Name: Triciribine

CAS#: 35943-35-2

Chemical Formula: C13H16N6O4

Exact Mass: 320.1233

Molecular Weight: 320.30

Elemental Analysis: C, 48.75; H, 5.03; N, 26.24; O, 19.98

Price and Availability

Size	Price	Availability
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

35943-35-2 61966-08-3

Synonym

VQD-002; VQD 002; VQD002; NSC-154020; NSC 154020; NSC154020; Triciribine.

IUPAC/Chemical Name

(2R,3R,4S,5R)-2-(3-amino-5-methyl-1,4,5,6,8-pentaazaacenaphthylen-1(5H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol.

InChi Key

HOGVTUZUJGHKPL-HTVVRFAVSA-N

InChi Code

InChI=1S/C13H16N6O4/c1-18-11-7-5(10(14)17-18)2-19(12(7)16-4-15-11)13-9(22)8(21)6(3-20)23-13/h2,4,6,8-9,13,20-22H,3H2,1H3,(H2,14,17)/t6-,8-,9-,13-/m1/s1

SMILES Code

O[C@H]1[C@H](N2C=C3C(N)=NN(C)C4=NC=NC2=C34)O[C@H](CO)[C@H]1O

Appearance

Tan solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 320.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sato-Nagaoka Y, Suzuki S, Suzuki S, Takahashi S. Combination of triciribine and p38 MAPK inhibitor PD169316 enhances the differentiation effect on myeloid leukemia cells. PLoS One. 2024 Dec 31;19(12):e0312406. doi: 10.1371/journal.pone.0312406. PMID: 39739720; PMCID: PMC11687802. 2: Yang JP, Toughiri R, Gounder AP, Scheibe D, Petrus M, Fink SJ, Vallee S, Kenniston J, Papaioannou N, Langston S, Gavva NR, Horman SR. Identification of small molecule agonists of fetal hemoglobin expression for the treatment of sickle cell disease. PLoS One. 2024 Nov 6;19(11):e0307049. doi: 10.1371/journal.pone.0307049. PMID: 39504332; PMCID: PMC11540224. 3: Curcio AG, Ribeiro TIS, Gomes HF, Carvalho CSP, Bussiere MCC, Dias AJB. Increased in vitro production of bovine embryos resulting from oocyte maturation in the presence of triciribine, a specific inhibitor of AKT. Theriogenology. 2025 Jan 1;231:222-227. doi: 10.1016/j.theriogenology.2024.10.024. Epub 2024 Oct 24. PMID: 39488152. 4: Poustforoosh A. Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors. Mol Biotechnol. 2024 Oct 27. doi: 10.1007/s12033-024-01307-2. Epub ahead of print. PMID: 39463205. 5: Takahashi S. Signaling effect, combinations, and clinical applications of triciribine. J Chemother. 2024 Sep 14:1-9. doi: 10.1080/1120009X.2024.2403050. Epub ahead of print. PMID: 39275964. 6: Singh AK, Singh J, Goode NA, Laezza F. Crosstalk among WEE1 Kinase, AKT, and GSK3 in Nav1.2 Channelosome Regulation. Int J Mol Sci. 2024 Jul 24;25(15):8069. doi: 10.3390/ijms25158069. PMID: 39125637; PMCID: PMC11311446. 7: Chen M, Ji T, Liu YY, Liu WL, Yan XT, Jiang HX, Zhang ZZ, He XH. Emodin alleviates intestinal ischemia/reperfusion-induced lung injury by upregulating HO-1 expression via PI3K/AkT pathway. Surgery. 2024 Aug;176(2):499-510. doi: 10.1016/j.surg.2024.04.006. Epub 2024 May 28. PMID: 38811326. 8: Suzuki S, Suzuki S, Sato-Nagaoka Y, Ito C, Takahashi S. Identification of triciribine as a novel myeloid cell differentiation inducer. PLoS One. 2024 May 14;19(5):e0303428. doi: 10.1371/journal.pone.0303428. PMID: 38743735; PMCID: PMC11093380. 9: Santagata S, Rea G, Bello AM, Capiluongo A, Napolitano M, Desicato S, Fragale A, D'Alterio C, Trotta AM, Ieranò C, Portella L, Persico F, Di Napoli M, Di Maro S, Feroce F, Azzaro R, Gabriele L, Longo N, Pignata S, Perdonà S, Scala S. Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients. Br J Cancer. 2024 Jun;130(12):2016-2026. doi: 10.1038/s41416-024-02702-x. Epub 2024 May 4. PMID: 38704478; PMCID: PMC11183124. 10: Chen M, Lv J, Guo N, Ji T, Fang Y, Wang Z, He X. Crtc1 deficiency protects against sepsis-associated acute lung injury through activating akt signaling pathway. J Inflamm (Lond). 2024 Apr 22;21(1):12. doi: 10.1186/s12950-024-00385-y. PMID: 38644501; PMCID: PMC11034098. 11: Ye M, Liu T, Miao L, Zou S, Ji H, Zhang J, Zhu X. The Role of ZNF275/AKT Pathway in Carcinogenesis and Cisplatin Chemosensitivity of Cervical Cancer Using Patient-Derived Xenograft Models. Cancers (Basel). 2023 Nov 28;15(23):5625. doi: 10.3390/cancers15235625. PMID: 38067329; PMCID: PMC10705782. 12: Alanazi AH, Chastain DB, Rudraraju M, Parvathagiri V, Shan S, Lin X, Henao- Martínez AF, Franco-Paredes C, Narayanan SP, Somanath PR. A multi-arm, parallel, preclinical study investigating the potential benefits of acetazolamide, candesartan, and triciribine in combination with fluconazole for the treatment of cryptococcal meningoencephalitis. Eur J Pharmacol. 2023 Dec 5;960:176177. doi: 10.1016/j.ejphar.2023.176177. Epub 2023 Nov 4. PMID: 37931839; PMCID: PMC10985624. 13: Santos TO, Cruz-Filho JD, Costa DM, Silva RPD, Anjos-Santos HCD, Santos JRD, Reis LC, Kettelhut ÍDC, Navegantes LC, Camargo EA, Lauton-Santos S, Badauê- Passos D Jr, Mecawi AS, Lustrino D. Non-canonical Ca2+- Akt signaling pathway mediates the antiproteolytic effects induced by oxytocin receptor stimulation in skeletal muscle. Biochem Pharmacol. 2023 Nov;217:115850. doi: 10.1016/j.bcp.2023.115850. Epub 2023 Oct 12. PMID: 37832795. 14: Wu H, Ge J, Zou F, Jiang Z, Wang B, Yuan X, Long K, Liu J, Wang W, Liu Q. Pharmacological inhibiting STAT5 for the treatment of FLT3-ITD-positive acute myeloid leukemia with triciribine phosphate monohydrate. MedComm (2020). 2023 Jun 21;4(4):e294. doi: 10.1002/mco2.294. PMID: 37361897; PMCID: PMC10285034. 15: Takagi S, Onishi T, Takashima T, Shibahara K, Mori M. Acquired AKT-inhibitor Resistance Is Mediated by ATP-binding Cassette Transporters in Endometrial Carcinoma. Anticancer Res. 2023 Jun;43(6):2501-2507. doi: 10.21873/anticanres.16417. PMID: 37247888. 16: Shan S, Liu F, Ford E, Caldwell RB, Narayanan SP, Somanath PR. Triciribine attenuates pathological neovascularization and vascular permeability in a mouse model of proliferative retinopathy. Biomed Pharmacother. 2023 Jun;162:114714. doi: 10.1016/j.biopha.2023.114714. Epub 2023 Apr 18. PMID: 37080089; PMCID: PMC10208444. 17: Kusuma FK, Prabhu A, Tieo G, Ahmed SM, Dakle P, Yong WK, Pathak E, Madan V, Jiang YY, Tam WL, Kappei D, Dröge P, Koeffler HP, Jeitany M. Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT). Nat Commun. 2023 Apr 6;14(1):1919. doi: 10.1038/s41467-023-37633-3. PMID: 37024489; PMCID: PMC10079688. 18: Li M, Yu J, Deng H, Xie S, Li Q, Zhao Y, Yin S, Ji YF. Upregulation of glutamate transporter 1 by mTOR/Akt pathway in astrocyte culture during oxygen- glucose deprivation and reoxygenation. Exp Brain Res. 2023 Jan;241(1):201-209. doi: 10.1007/s00221-022-06514-4. Epub 2022 Nov 27. PMID: 36436003. 19: Wang G, Xu J, Ma H, Mu Y, Xu W, Yan N, Liu W, Zheng D, Huang X, Li L. Phenolipid JE improves metabolic profile and inhibits gluconeogenesis via modulating AKT-mediated insulin signaling in STZ-induced diabetic mice. Pharmacol Res. 2023 Jan;187:106569. doi: 10.1016/j.phrs.2022.106569. Epub 2022 Nov 24. PMID: 36427798. 20: Zhang XD, Sun SL, Wang G, Li XL, Yao LJ, Xu H, Zhang P, Shen L. [Protective effects of estrogen modified hBMSC on HG-induced injury of vascular endothelial cells]. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2022 Jul;38(4):289-294. Chinese. doi: 10.12047/j.cjap.6244.2022.054. PMID: 36414548.